Searching the Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Cell-based ex vivo gene therapy in solid organs, especially the liver, has proven technically challenging. Here, we report a feasible strategy for the clinical application of hepatocyte therapy. We first generated high-quality autologous hepatocytes through the large-scale expansion of patient-derived hepatocytes. Moreover, the proliferating patient-derived hepatocytes, together with the AAV2.7m8 variant identified through screening, enabled CRISPR-Cas9-mediated targeted integration efficiently, achieving functional correction of pathogenic mutations in FAH or OTC. Importantly, these edited hepatocytes repopulated the injured mouse liver at high repopulation levels and underwent maturation, successfully treating mice with tyrosinemia following transplantation. Our study combines ex vivo large-scale cell expansion and gene editing in patient-derived transplantable hepatocytes, which holds potential for treating human liver diseases.
Pubmed ID: 38772378
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets IgG (H+L)
View all literature mentionsThis polyclonal targets Alpha-1-Antitrypsin
View all literature mentionsThis monoclonal targets Cytokeratin 7 antibody [RCK105]
View all literature mentionsThis polyclonal targets Arginase 1
View all literature mentionsThis polyclonal targets CD31
View all literature mentionsThis unknown targets Goat IgG (H+L)
View all literature mentionsThis monoclonal targets HNF-4alpha (H-1)
View all literature mentionsThis unknown targets Mouse IgG (H+L)
View all literature mentionsThis monoclonal targets Human CYP3A4
View all literature mentionsThis polyclonal targets Albumin
View all literature mentionsThis polyclonal targets IgG (H+L)
View all literature mentionsThis monoclonal targets GAPDH antibody [EPR6256]
View all literature mentionsThis recombinant monoclonal targets Ornithine Carbamoyltransferase/OTC
View all literature mentionsThis monoclonal targets β-Actin
View all literature mentionsThis polyclonal targets Rabbit IgG (H+L)
View all literature mentions